User: prashantiyengar Topic: IP
Category: drugs :: india
Last updated: Oct 22 2014 10:59 IST RSS 2.0
 
1 to 20 of 2,441    
40 years ago and now: How Ranbaxy moved out of family control 22.10.2014 Rediff: Business
Ranbaxy did its maiden public issue in 1973.
Also found in: [+]
Government may propose sub-groups on other contentious issues under ambit of IPR panel 22.10.2014 ET: Pharma
During PM Modi’s visit to the US, the two countries committed to set up an annual high-level IP working group as part of the trade policy forum.
Also found in: [+]
Pharma companies feel law change can weaken ability to provide low-cost drugs 21.10.2014 ET: Pharma
Indian drugmakers are also concerned about a shift in India’s position on IPR, which they say is being keenly watched by many developing countries.
Also found in: [+]
DIPP seeks details on blood cancer drug Dasatinib for issuance of compulsory licences 19.10.2014 ET: Pharma
The ministry has sought details from the Health Ministry, which had approached the DIPP for issuance of compulsory licences.
Also found in: [+]
Medical charity accuses US of pushing India to ease patent rules 18.10.2014 ET: Pharma
India's stringent rules for obtaining patents and its $12.2-billion generics industry reduce incentives to produce cutting-edge medicines.
Also found in: [+]
DIPP defers decision on issuance of compulsory licence for cancer drug Dasatinib 16.10.2014 ET: Pharma
“DIPP has sought further information to justify the issuance of a CL under Section 92 of Indian Patents Act,” said an official privy to the matter."
Also found in: [+]
US to launch fresh review of India's patent regime 14.10.2014 ET: Policy
US Trade Representative has launched a fresh offensive against India's intellectual property rights regime, a move that may hamper bilateral dialogue with US.
Also found in: [+]
An old policy Modi must hold on to 14.10.2014 India Together

The government’s clarification on the Indo-US joint statement on Intellectual Property Rights issued during Modi’s visit to the United States highlights the imperative of maintaining India’s original stance on patent laws and refusal to yield to US demands made in its Special 301 Report. Shambhu Ghatak has more.

Also found in: [+]
US to launch fresh review of India's patent regime 14.10.2014 TOI: India Business
An OCR is a second stage of the Special 301 action and being an extreme measure, the US authorities can impose sanctions after putting the country in the "priority foreign watch" category.
Also found in: [+]
Over the counter drug market to reach $6.6 billion by 2016 5.10.2014 ET: Pharma
Pharma companies have increased spending to tap rural markets. The market share of hospitals is expected to increase from 13.1& in 2009 to 26% in 2020
Also found in: [+]
Has PM Narendra Modi bowed to US pressure on patent laws? 3.10.2014 ET: Policy
According to the US-India joint statement, the leaders agreed on the need to foster innovation in a manner that promoted economic growth and job creation.
Also found in: [+]
Has PM Modi bowed to US pressure on patent laws? 3.10.2014 TOI: Home
A paragraph buried in the US-India joint statement, which talks of establishing an annual high-level Intellectual Property (IP) working group as part of the Trade Policy Forum, has made health activists across the world apprehensive.
Also found in: [+]
US health experts express concern over working group on intellectual property 2.10.2014 ET: Pharma
Obama and Modi in a joint statement issued on Tuesday committed to establish an annual high-level Intellectual Property (IP) Working Group.
Also found in: [+]
Pharmaceutical companies refute Congress' post claiming hike in prices of life-saving drugs 2.10.2014 ET: Pharma
Novartis, which owns patent for Glivec globally but excluding India, and Natco Pharma, whose generic version of drug was also listed on website.
Also found in: [+]
Modi must resist U.S. pressure on drug patents - MSF 30.9.2014 Sify Finance
Also found in: [+]
Industrial policy repair 30.9.2014 Telegraph: Opinion
After having his fill of sushi, the prime minister is back home and in the saddle, and has renewed his campaign to revive industry. This is a departure from his predecessor's approach of laissez faire. Another change is that Narendra Modi has invited manufacturers from abroad to come and make things in India. That is a bit surprising. His party has always believed in Little India. Indian industrialists have been its supporters; they cannot be enthusiastic about competition from foreigners bringing the latest technology and building brand new factories in India. But Modi must have done his political homework; let me concentrate on how best he can achieve his aim.
Also found in: [+]
Will Modi bow to US pressure to modify India’s pro-people patent law? 23.9.2014 TOI: India
A large number of civil society groups and public intellectuals have issued a public statement expressing concern over the government’s decision to review India’s positions on intellectual property ...
Also found in: [+]
Intellectual Property Rights and India's competitiveness 22.9.2014 ET: Policy
According to the most recent IP Index by GIPC of the US Chamber of Commerce, India's rank is the last among 25 countries for which the Center prepares the Index.
Also found in: [+]
IPR and India's competitiveness (Column: Active Voice) 22.9.2014 Sify Finance
. They also have an impact on the FDI inflows in a developing country, which helps not just in terms of capital inflows, but also in terms of technology and expertise. Strengthening IPR thus becomes imperative from the viewpoint of economic development. According to the most recent IP Index by GIPC (Global Intellectual Property Center) of the US Chamber of Commerce, India's rank is the last among 25 countries for which the Center prepares the Index. It is alarming, and steps need to be taken to ensure we do better on various aspects covered under the specific index.
Also found in: [+]
Irritants on Modi itinerary 21.9.2014 Telegraph: Business
New Delhi, Sept. 21: Prime Minister Narendra Modi's trip to the US later this week will give the Obama administration an opportunity to not only woo an important ally in Asia but also take up issues ranging from India's pharma patent regime to its stand at the World Trade Organization.
Also found in: [+]
1 to 20 of 2,441